-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 10, a group of listed pharmaceutical companies issued announcements, including companies such as Hengrui, Zhaoyan New Pharmaceuticals, and Shuangcheng Pharmaceuticals.
The content of the announcements was related to reductions in holdings, drug approvals, and cooperation
.
Shuangcheng Pharmaceutical: Subsidiary has obtained 4 utility model patent certificates.
Shuangcheng Pharmaceutical issued an announcement.
The company's holding subsidiary Ningbo Shuangcheng Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Ningbo Shuangcheng") recently obtained 4 utility model patents Certificate, the patent name is "a medicine crushing and granulating machine", "an adjustable aluminum-plastic packaging equipment", "a biopharmaceutical freeze dryer tray mechanism" and "a portable infrared moisture analyzer for pharmaceuticals" "
.
Zhaoyan New Drug: Three directors, supervisors and senior executives reduced their holdings of 47,500 shares in total.
Zhaoyan New Drug issued an announcement that the company’s supervisors Sun Huiye, Yin Lili, and Li Ye disclosed the reduction plan and self-reduction plan on April 14, 2021 Within 6 months after 15 trading days from the date of the announcement, the Shanghai Stock Exchange will reduce its holdings by no more than 30,900 shares, 16,500 shares, and 12,500 shares through centralized auction trading, which does not exceed 0.
022% of the company's total share capital at that time
.
As of the date of this announcement, the time for the share reduction plan expired, and the company’s supervisors Sun Huiye, Yin Lili and Li Ye reduced their holdings by 30,000 shares, 10,500 shares, and 7,000 shares, respectively
.
Hengrui Pharmaceuticals: Two drugs from its subsidiaries have been approved for clinical trials Hengrui Pharmaceuticals has announced that its subsidiary Suzhou Shengdia Biomedical Co.
, Ltd.
's SHR-1701 injection and Shanghai Hengrui Pharmaceutical Co.
, Ltd.
's SHR2285 tablets have been approved for clinical trials
.
Among them, SHR-1701 can promote the activation of effector T cells, and can also effectively improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells
.
SHR2285 tablets are intended to prevent or treat arteriovenous thrombosis and reduce the risk of thromboembolism caused by interventional therapy or cardiopulmonary bypass
.
Meirui Health International: cancellation of 22.
704 million repurchased shares Meirui Health International announced that on November 10, 2021, the company cancelled 22.
704 million repurchased shares
.
Ruizhi Medicine: Shareholders of Ruiyun Investment and its concerted parties will reduce their holdings by no more than 1% of the company's shares
.
Yan'an Bikang: Signed a strategic cooperation agreement with Guanyou Capital.
Yan'an Bikang announced that the company and Guanyou Capital will "hand in hand", and the two parties intend to reach a cooperative relationship.
With the help of the company's industrial advantages, the capital advantages and resource advantages of Guanyou Capital, both parties will realize Mutual benefit, resource sharing, complementary advantages, and jointly promote the development of the company's related industries
.
It is understood that Guanyou Capital is a fund management company under the Nanjing State-owned Mixed Reform Fund.
It has initiated the establishment of six equity investment funds (or limited partnerships) such as Zijin Pharmaceutical and Zijin Putuo
.
The total scale of entrusted management funds is nearly 9 billion yuan .
It is worth mentioning that on November 10th, Jiangsu Jiujiu Technology Co.
, Ltd.
(“Jujiujiu Technology”), a subsidiary of Yan’an Bikang, also obtained nearly 200 Intensive research and investigation by institutions
.
Jichuan Pharmaceutical: Signed the exclusive development, production and sales cooperation agreement of Yitan growth hormone (TJ101) Exclusive development, production and sales cooperation agreement, the first payment and milestone payment paid by Jichuan Pharmaceutical will not exceed 2.
016 billion yuan
.
The content of the announcements was related to reductions in holdings, drug approvals, and cooperation
.
Shuangcheng Pharmaceutical: Subsidiary has obtained 4 utility model patent certificates.
Shuangcheng Pharmaceutical issued an announcement.
The company's holding subsidiary Ningbo Shuangcheng Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Ningbo Shuangcheng") recently obtained 4 utility model patents Certificate, the patent name is "a medicine crushing and granulating machine", "an adjustable aluminum-plastic packaging equipment", "a biopharmaceutical freeze dryer tray mechanism" and "a portable infrared moisture analyzer for pharmaceuticals" "
.
Zhaoyan New Drug: Three directors, supervisors and senior executives reduced their holdings of 47,500 shares in total.
Zhaoyan New Drug issued an announcement that the company’s supervisors Sun Huiye, Yin Lili, and Li Ye disclosed the reduction plan and self-reduction plan on April 14, 2021 Within 6 months after 15 trading days from the date of the announcement, the Shanghai Stock Exchange will reduce its holdings by no more than 30,900 shares, 16,500 shares, and 12,500 shares through centralized auction trading, which does not exceed 0.
022% of the company's total share capital at that time
.
As of the date of this announcement, the time for the share reduction plan expired, and the company’s supervisors Sun Huiye, Yin Lili and Li Ye reduced their holdings by 30,000 shares, 10,500 shares, and 7,000 shares, respectively
.
Hengrui Pharmaceuticals: Two drugs from its subsidiaries have been approved for clinical trials Hengrui Pharmaceuticals has announced that its subsidiary Suzhou Shengdia Biomedical Co.
, Ltd.
's SHR-1701 injection and Shanghai Hengrui Pharmaceutical Co.
, Ltd.
's SHR2285 tablets have been approved for clinical trials
.
Among them, SHR-1701 can promote the activation of effector T cells, and can also effectively improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells
.
SHR2285 tablets are intended to prevent or treat arteriovenous thrombosis and reduce the risk of thromboembolism caused by interventional therapy or cardiopulmonary bypass
.
Meirui Health International: cancellation of 22.
704 million repurchased shares Meirui Health International announced that on November 10, 2021, the company cancelled 22.
704 million repurchased shares
.
Ruizhi Medicine: Shareholders of Ruiyun Investment and its concerted parties will reduce their holdings by no more than 1% of the company's shares
.
Yan'an Bikang: Signed a strategic cooperation agreement with Guanyou Capital.
Yan'an Bikang announced that the company and Guanyou Capital will "hand in hand", and the two parties intend to reach a cooperative relationship.
With the help of the company's industrial advantages, the capital advantages and resource advantages of Guanyou Capital, both parties will realize Mutual benefit, resource sharing, complementary advantages, and jointly promote the development of the company's related industries
.
It is understood that Guanyou Capital is a fund management company under the Nanjing State-owned Mixed Reform Fund.
It has initiated the establishment of six equity investment funds (or limited partnerships) such as Zijin Pharmaceutical and Zijin Putuo
.
The total scale of entrusted management funds is nearly 9 billion yuan .
It is worth mentioning that on November 10th, Jiangsu Jiujiu Technology Co.
, Ltd.
(“Jujiujiu Technology”), a subsidiary of Yan’an Bikang, also obtained nearly 200 Intensive research and investigation by institutions
.
Jichuan Pharmaceutical: Signed the exclusive development, production and sales cooperation agreement of Yitan growth hormone (TJ101) Exclusive development, production and sales cooperation agreement, the first payment and milestone payment paid by Jichuan Pharmaceutical will not exceed 2.
016 billion yuan
.
